Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Severstal's capex in 2025 will be ₽169 billion

2/3/25 CHMF

Severstal sales to grow by 1% in 2024

2/3/25 CHMF

Rosseti proposed to change the procedure for calculating payment for its services

2/3/25 FEES

MGKL revenue in January increased 4.7 times

2/3/25 MGKL

SPB Exchange summarized the results of trading in 2024

1/31/25 SPBE

Shares of Ashinskiy Metzavod will cease to be traded from March 13

1/31/25 AMEZ

Smarttechgroup will allocate 50% of its profits to dividends

1/31/25 CARM

Fesco increased transportation through land border crossings from China by 66%

1/31/25 FESH

Unipro's output in 2024 increased by 0.4%

1/31/25 UPRO

Smarttechgroup aims to earn ₽3 billion in profits by 2028

1/31/25 CARM